Over-expression of COX-2 mRNA in colorectal cancer

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Roelofs, Hennie M J ^a   te Morsche, Rene H M ^a   van Heumen, Bjorn W H ^a   Nagengast, Fokko M ^a   Peters, Wilbert H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOOXYGENASE 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA;

ADULT; AGED; ARTICLE; B2M GENE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GAPDH GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HOUSEKEEPING GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE LEVEL; TUMOR LOCALIZATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; CARCINOMA; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION; GENETIC MARKERS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84891652124     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-14-1     Document Type: Article

References (28)

1. Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome Biol 2004, 5:241. 10.1186/gb-2004-5-9-241, 522864, 15345041.
2. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc Natl Acad Sci U S A 2002, 99:13926-13931. 10.1073/pnas.162468699, 129799, 12242329.
3. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995, 55:3785-3789.
4. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107:1183-1188.
5. Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K. Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterology 2006, 12:1336-1345.
6. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005, 23:2840-2855.
7. Mehta S, Boddy A, Johnson T, Rhodes M. Systematic review: cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis. Aliment Pharmacol Ther 2006, 24:1321-1331. 10.1111/j.1365-2036.2006.03119.x, 17059513.
8. Liu X, Li P, Zhang ST, You H, Jia JD, Yu ZL. COX-2 mRNA expression in esophageal squamous cell carcinoma (ESCC) and effect by NSAID. Dis Esophagus 2008, 21:9-14.
9. Buskens CJ, Van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ, Offerhaus GJ, Van Lanschot JJ, Ristimäki A. Prognostic significance of elevated cyclooxygenase-2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002, 122:1800-1807. 10.1053/gast.2002.33580, 12055587.
10. Buttar NS, Wang KK, Leontovich O, Westcott J, Pacifico RJ, Anderson MA, Krishnadeth KK, Lutzke LS, Burgart LJ. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002, 122:1101-1112. 10.1053/gast.2002.32371, 11910360.
11. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386. 10.1093/carcin/bgp014, 19136477.
12. Antonacopoulou AG, Tsamandas AC, Petsas T, Liava A, Scopa CD, Papavassiliou AG, Kalofonos HP. EGFR, HER-2 and COX-2 levels in colorectal cancer. Histopathology 2008, 53:698-706. 10.1111/j.1365-2559.2008.03165.x, 19102009.
13. Brosens LA, Keller JJ, Pohjola L, Haglund C, Morsink FH, Iacobuzio-Donahue C, Goggins M, Giardiello FM, Ristimäki A, Offerhaus GJ. Increased expression of cytoplasmic HuR in familial adenomatous polyposis. Cancer Biol Ther 2008, 7:424-427. 10.4161/cbt.7.3.5417, 18094611.
14. Nosho K, Yoshida M, Yamamoto H, Taniguchi H, Adachi Y, Mikami M, Hinoda Y, Imai K. Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis. Carcinogenesis 2005, 26:892-899.
15. Loukanov T, Kirilov M, Fürstenberger G, Müller-Decker K. Localization of cyclo-oxygenase-2 in human recurrent colorectal cancer. Clin Invest Med 2010, 33:E22-E29.
16. Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Wang W, Lönnroth C, Lundholm K. EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer 2007, 121:232-240. 10.1002/ijc.22582, 17290397.
17. Delage B, Rullier A, Capdepont M, Rullier E, Cassand P. The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers. Nutr J 2007, 6:20. 10.1186/1475-2891-6-20, 2018695, 17767717.
18. Jahns F, Wilhelm A, Jablonowski N, Mothes H, Radeva M, Wölfert A, Greulich KO, Glei M. Butyrate suppresses mRNA increase of osteopontin and cyclooxygenase-2 in human colon tumor tissue. Carcinogenesis 2011, 32:913-920. 10.1093/carcin/bgr061, 3314284, 21459756.
19. Pfaffl MW, Georgieva TM, Georgiev IP, Ontsouka E, Hageleit M, Blum JW. Real-time RT-PCR quantification of insulin-like growth factor (IGF)-1, IGF-1 receptor, IGF-2, IGF-2 receptor, insulin receptor, growth hormone receptor, IGF-binding proteins 1, 2 and 3 in the bovine species. Domest Anim Endocrinol 2002, 22:91-102. 10.1016/S0739-7240(01)00128-X, 11900967.
20. Carvalho B, Sillars-Hardebol AH, Postma C, Mongera S, Droste JT, Obulkasim A, van de Wiel M, van Criekinge W, Ylstra B, Fijneman RJ, Meijer GA. Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism. Cell Oncol 2012, 35:53-63.
21. Hamaya Y, Yoshida K, Takai T, Ikuma M, Hishida A, Kanaoka S. Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer. Br J Cancer 2010, 102:916-921. 10.1038/sj.bjc.6605564, 2833255, 20145612.
22. Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology 2004, 127:422-427. 10.1053/j.gastro.2004.05.022, 15300574.
23. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW, Span PN. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 2005, 85:154-159. 10.1038/labinvest.3700208, 15543203.
24. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55:611-622. 10.1373/clinchem.2008.112797, 19246619.
25. Caradec J, Sirab N, Revaud D, Keumeugni C, Loric S. Is GAPDH a relevant housekeeping gene for normalisation in colorectal cancer experiments?. Br J Cancer 2010, 103:1475-1476. 10.1038/sj.bjc.6605851, 2990595, 20859286.
26. Barber RD, Harmer DW, Coleman RA, Clark BJ. GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol Genomics 2005, 21:389-395. 10.1152/physiolgenomics.00025.2005, 15769908.
27. Stürzenbaum SR, Kille P. Control genes in quantitative molecular biological techniques: the variability of invariance. Comp Biochem Physiol B Biochem Mol Biol 2001, 130:281-289. 10.1016/S1096-4959(01)00440-7, 11567890.
28. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000, 25:169-193. 10.1677/jme.0.0250169, 11013345.